Asset
LENABASUM
Corbus Pharmaceuticals Holdings Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02465437 | phase2 | terminated | 2015-08-01 | 2016-10-01 | Corbus Pharmaceuticals Inc. | Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis |
| NCT02465450 | phase2 | completed | 2015-09-29 | 2016-12-28 | Corbus Pharmaceuticals Inc. | Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis |
| NCT02466243 | phase2 | terminated | 2015-06-01 | 2017-08-01 | Corbus Pharmaceuticals Inc. | Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis |
FDA applications (0)
This company has no applications containing this asset.